Orpathys Savolitinib Tablets Application Scope

Orpathys® (savolitinib) tablets are indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations.

Orpathys Savolitinib Tablets Characteristics

Ingredients: Each tablet contains 200 mg of savolitinib.
Properties: White to off-white, round, biconvex, film-coated tablets.
Packaging Specification: Bottles containing 30 tablets.
Storage: Store in a cool, dry place, protected from light.
Expiry Date: Refer to the packaging for the expiration date.
Executive Standard: Complies with the Chinese Pharmacopoeia 2020 edition.
Approval Number: National Medical Products Administration (NMPA) Approval No. H20210001.
Date of Revision: January 2025.
Manufacturer: HUTCHMED (China) Limited.

Guidelines for the Use of Orpathys Savolitinib Tablets

Dosage and Administration:
- Recommended Dose: 600 mg once daily.
- Administration: Oral intake, preferably after meals.
- Missed Dose: If a dose is missed, take it as soon as remembered unless it’s almost time for the next dose. Do not double doses to make up for a missed dose.
Adverse Reactions:
- Common Adverse Reactions: Nausea, vomiting, diarrhea, fatigue, peripheral edema, elevated liver enzymes.
- Serious Adverse Reactions: Interstitial lung disease, heart failure, severe liver dysfunction.
Contraindications:
- Hypersensitivity to savolitinib or any of its components.
- Pregnancy and breastfeeding.
Precautions:
- Monitor liver function regularly during treatment.
- Discontinue use if signs of interstitial lung disease or severe liver toxicity occur.
- Use with caution in patients with pre-existing heart conditions.

Orpathys Savolitinib Tablets Interactions

CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors may increase savolitinib plasma concentrations.
CYP3A4 Inducers: Co-administration with strong CYP3A4 inducers may decrease savolitinib plasma concentrations.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.